Master Pharm suspends IPO

Master Pharm, after consultation with offering - Trigon DM, has decided to suspend their public offer due to the unfavorable situation in the financial market, the company reported. "Carrying out the offer in such a difficult and uncertain market situation would, in our view,  not be a rational action. We will reconsider the matter when the situation on the stock market stabilizes," Jacek Franasik, the CEO at Master Pharm said. A new deadline will be announced later. Master Pharm's offer included up to 6.85 million shares. The maximum issue price was fixed at PLN 8.